{"SPADE_UN_11330": {"Clinical Information": [{"Medical use": "①Prevention of Ventilator-Associated Pneumonia; ②Prevention of oral complications caused by radiation therapy for head and neck cancer.", "Company": "Intrabiotics Pharmaceuticals Inc.(Mountain View, CA)", "Stage of Development": "Phase III(Failure)", "Comments": "Based on the pig peptide protegrin, Iseganan possesses broad-spectrum activity in vitro against bacteria and fungi; however, in clinical trials it failed to prevent or reduce oral mucositis compared with a placebo", "Clinical Trials": ["NCT00022373", "NCT00118781"]}], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_11330", "Peptide Name": "Iseganan(IB-367)", "Sequence": "RGGLCYCRGRFCVCVGR", "Source": "A synthetic analogue of Protegrin I (IBL-367, the pig protegrin derivative), extracted from porcine leukocytes.", "Target Organism": "Gram-positive bacteria:\nStreptococcus salivarius (12) (MIC=0.2-5.0 μg/ml), S. sanguis (14) (MIC=4-64 μg/ml), S. mitis (15) (MIC=2-43 μg/ml), S. mutans (3) (MIC=0.7-1.3 μg/ml), Streptococcus spp. group D (6) (MIC=0.25-4 μg/ml), Streptococcus spp. (16) (MIC=1.3-16 μg/ml), Corynebacterium spp. (5) (MIC=0.13-0.25 μg/ml), Staphylococcus spp. (35) (MIC=0.13-4 μg/ml), Methicillin-resistant S. aureus (MRSA; ATCC 33591) (MIC=4 μg/ml);\nGram-negative bacteria:\nPseudomonas aeruginosa (ATCC 9027) (MIC=2 μg/ml), Moraxella spp. (12) (MIC=0.2-0.8 μg/ml), Neisseria sp. (1) (MIC=8 μg/ml), Haemophilus spp. (15) (MIC=1-8 μg/ml), Acinetobacter calcoaceticus (4) (MIC=0.06-2 μg/ml), Klebsiella pneumoniae (4) (MIC=1-5 μg/ml), Pseudomonas aeruginosa (18) (MIC=1-8 μg/ml), Escherichia coli (5) (MIC=0.25-1 μg/ml), Serratia marcescens (16), (MIC=16-256 μg/ml).\nFungi:\nCandida albicans (6) (MIC=4-16 μg/ml).", "Reference": ["A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukoc. Res.(2004).(PMID:15120931)A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int. J. Radiat. Oncol. Biol. Phys.(2004)(PMID:22077420)", "A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukoc. Res.(2004).(PMID:15120931)", "A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int. J. Radiat. Oncol. Biol. Phys.(2004)(PMID:22077420)"], "Biological Activity": ["Antibacterial", "Antifungal"], "Frequent Amino Acids": "CGR", "Absent Amino Acids": "ADEHIKMNOPQSTUW", "Basic Residues": 4, "Acidic Residues": 0, "Hydrophobic Residues": 5, "Polar Residues": 11, "Positive Residues": 4, "Negative Residues": 0, "Mass": 1905.3, "PI": 9.37, "Net Charge": 4, "Hydrophobicity": 0.24, "Similar Sequences": [{"SPADE_ID": "SPADE_UN_12923", "Similarity": 1.0, "Sequence": "GRRGGRGGRGR"}, {"SPADE_ID": "SPADE_N_02574", "Similarity": 0.9411764705882353, "Sequence": "RGGRLCYCRPRFCVCVGR"}, {"SPADE_ID": "SPADE_N_04200", "Similarity": 0.9411764705882353, "Sequence": "RGGRLCYCRRRFCVCVGR"}]}}}